Silence Therapeutics (SLN) Stock Price & How to Invest
Last updated November 2026
Short answer
Silence Therapeutics plc is a UK-based clinical-stage biotech developing siRNA (gene silencing) medicines, and its American Depositary Shares trade on Nasdaq under SLN, with each ADS representing 3 ordinary shares. At about $8.81 on October 16, 2026 the stock carries a market cap of roughly $548 million. In August 2026 divesiran met the primary endpoint of its Phase 2 SANRECO trial in polycythemia vera and the company raised about $201 million in gross proceeds from an upsized ADS offering, so the shares now represent a Phase 3-bound hematology drug plus zerlasiran for high lipoprotein(a), rather than a revenue stream.
SLN stock price
As of 2026-11-16, Silence Therapeutics (SLN) last closed at $19.80, up 195.5% over the past year. Over the past 52 weeks it has traded between $4.30 and $19.83.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Silence Therapeutics's investor relations page. Walnut is informational, not investment advice.
SLN key stats
At $19.80 on November 16, 2026, Silence Therapeutics (SLN) has a market cap of $1.2B.
- Market cap
- $1.2B
- Price to book
- 24.3
- Beta
- 1.34
Market cap, P/E and yield are measured at the $19.80 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Silence Therapeutics (SLN)?
The last two weeks for Silence Therapeutics, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- SLN closed at $19.80 on November 16, 2026, up 0.3% over the past five trading days (from $19.75).
- On November 13, 2026, Silence Therapeutics filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 12, 2026, Silence Therapeutics filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Silence Therapeutics (SLN) do?
Silence Therapeutics plc is a London-headquartered biotechnology company built around short interfering RNA, a class of drug that switches off the production of a specific disease-causing protein in the liver rather than blocking it after the fact. Its proprietary discovery platform, marketed as mRNAi GOLD, attaches a GalNAc sugar to the siRNA so the molecule is taken up by liver cells, which is the same delivery approach behind the approved RNAi drugs on the market today. Two candidates carry the story. Zerlasiran silences the LPA gene to lower lipoprotein(a), an inherited cardiovascular risk factor with no approved therapy, and produced reductions of more than 80 percent in its Phase 2 ALPACAR-360 trial. Divesiran targets TMPRSS6 to raise hepcidin and control red blood cell production in polycythemia vera, a chronic blood cancer whose patients are otherwise managed with repeated therapeutic phlebotomy. A third asset, SLN312, was returned to Silence in March 2026 after AstraZeneca elected not to advance it past Phase 1.
The investment picture is still binary, but the first big binary has now landed. On August 10, 2026 Silence reported that divesiran met the primary endpoint of the Phase 2 SANRECO trial: 88% of patients were responders (no phlebotomy and hematocrit below 45% during weeks 18-36) against 19% on placebo, and divesiran patients averaged 0.2 phlebotomies over 36 weeks versus 2.1 on placebo, with no new safety findings. A Phase 3 trial of every-12-week dosing against placebo is expected to start in the first half of 2027. The company used the moment to sell about 14.9 million ADSs at $13.50 each, including the underwriters' full option, for gross proceeds of about $201 million, adding substantially to the roughly $72 million of cash and short-term investments it held at June 30, 2026. Collaboration revenue remains negligible (about $0.6 million on a trailing basis, down from roughly $34 million in 2024), and management still says it will start zerlasiran's Phase 3 cardiovascular outcomes trial only once a partner is secured. The stock has given back much of its post-data jump: it closed near $8.81 on October 16, 2026, below the $13.50 offering price and down about 28% in the past month, though still up about 43% year to date and 34% over one year.
What's driving Silence Therapeutics (SLN)?
1. Divesiran after a positive SANRECO Phase 2
The SANRECO readout arrived in August 2026 and met its primary endpoint: an 88% responder rate on divesiran versus 19% on placebo (p<0.0001), with 93.8% responding on every-6-week dosing and 81.3% on every-12-week dosing among 48 phlebotomy-dependent patients. Divesiran patients needed an average of 0.2 phlebotomies over 36 weeks against 2.1 on placebo. Silence owns the program outright and plans a Phase 3 of every-12-week dosing versus placebo starting in the first half of 2027. The open questions now are Phase 3 design, cost, and timing, and how the data compares with Protagonist and Takeda's rusfertide once full results are presented at a medical congress.
2. A partner for zerlasiran
Zerlasiran is described as Phase 3 ready for lipoprotein(a) driven cardiovascular disease, with the core readiness work finished, but Silence has committed to starting the outcomes trial only after securing a third party to fund it. A cardiovascular outcomes trial in this setting runs for years and costs far more than the company's current cash balance, so the deal itself, not the science, is the gating item. Terms of any such agreement, including upfront cash and retained economics, would set how much of the asset shareholders still own.
3. A larger cash pile after the August raise
Quarterly research spend was cut by more than half year over year in early 2026, and net losses ran about $11 million in the first quarter and about $9 million in the second. Before the offering, about $72 million of cash and short-term investments at June 30, 2026 was guided to fund operations into 2028. The August 2026 upsized offering then brought in about $201 million gross at $13.50 per ADS, which gives Silence the capacity to fund a divesiran Phase 3 itself, at the cost of roughly 15 million new ADSs, about a third more than the roughly 47 million outstanding earlier in the year.
4. Platform optionality beyond the lead assets
The mRNAi GOLD platform has generated liver-directed candidates across cardiovascular, hematology and metabolic targets, including early work on siRNA approaches to obesity. SLN312 came back in-house in March 2026 when AstraZeneca declined to continue past Phase 1, giving Silence full global rights to evaluate on its own terms. Platform breadth matters mainly as a source of future partnering revenue, since the company has neither the capital nor the intent to develop everything alone.
What are the risks to Silence Therapeutics (SLN)?
Silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings. The SANRECO Phase 2 succeeded, but Phase 2 results in 48 patients do not guarantee a Phase 3 win, and the planned Phase 3 will take years and consume a large part of the cash raised in August 2026. A partner for zerlasiran may not appear on acceptable economics or at all, which would leave the larger asset stranded. Dilution is no longer hypothetical: the August offering added about 14.9 million ADSs at $13.50, and the stock has since traded well below that price, closing near $8.81 on October 16, 2026 after a 28% fall in a month. Competition is well funded on both fronts: several large pharmaceutical companies are running Phase 3 lipoprotein(a) programs, and polycythemia vera already has approved and late-stage alternatives, including rusfertide aimed at the same hepcidin biology. Because the ADSs represent three ordinary shares each, per-share figures quoted for the Nasdaq listing and the underlying UK share count are not directly comparable, which is a frequent source of confusion when reading coverage.
What is the Silence Therapeutics (SLN) forecast?
4 analysts publish price targets on SLN, averaging $19.75 as of November 2026, or -0.3% against the $19.80 share price on November 16, 2026. The published targets run from $19.00 to $20.00, a narrow spread, and the ratings split 1 buy, 4 hold, 0 sell. Over the last six months there has been 1 raise and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full SLN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is SLN a buy or a sell?
We give no verdict on Silence Therapeutics. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Divesiran after a positive SANRECO Phase 2. The SANRECO readout arrived in August 2026 and met its primary endpoint: an 88% responder rate on divesiran versus 19% on placebo (p<0.0001), with 93.8% responding on every-6-week dosing and 81.3% on every-12-week dosing among 48 phlebotomy-dependent patients. The most optimistic published target, $20.00, assumes this works close to its best case.
The case against. Silence generates essentially no product revenue, so the equity is a claim on clinical outcomes and financing terms rather than on earnings. The most pessimistic target, $19.00, is roughly what SLN is worth if this bites instead.
Read the full bull and bear case on SLN, including what would have to change to break either one. Walnut is not an investment adviser.
Has Silence Therapeutics (SLN) split its stock?
No. Silence Therapeutics (SLN) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Silence Therapeutics (SLN) valued?
Market cap, P/E and dividend yield at today's price are in the SLN key stats above. The business figures below come from Silence Therapeutics's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$0.6M (collaboration revenue only, down from ~$34M in FY2024)
- Net loss (TTM): ~$60M; Q2 2026 net loss ~$9M
- Cash and short-term investments (June 30, 2026): ~$72M, before ~$201M gross raised in August 2026
- August 2026 offering: ~14.9M ADSs at $13.50, including full underwriter option
As of October 2026: Conventional valuation multiples do not apply: trailing revenue is under $1 million, so price-to-sales (about 890x) and price-to-earnings are arithmetic noise. Adding the roughly $201 million of gross offering proceeds to the $72 million held at June 30 suggests cash in the region of $250 million or more after fees and third-quarter spending, so a roughly $548 million market cap implies the market values divesiran, zerlasiran and the platform at about $300 million. Figures are approximate and as of October 16, 2026; the third-quarter report, expected around November 5 (an estimated date), will show the actual post-raise cash balance.
Who competes with Silence Therapeutics (SLN)?
RNA-based medicine developers
Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals and Ionis Pharmaceuticals are the reference set for liver-directed genetic medicine. Alnylam is the commercial benchmark with multiple approved RNAi products, Arrowhead competes directly on GalNAc-conjugated siRNA chemistry and partnering economics, and Ionis uses antisense oligonucleotides to reach many of the same targets. All three are larger, better capitalized and can fund late-stage trials without a partner, which is precisely the constraint shaping Silence's strategy.
Lipoprotein(a) lowering programs
Zerlasiran's field is crowded at the top. Novartis is furthest along with pelacarsen, an antisense drug already in a cardiovascular outcomes trial, while Amgen's olpasiran is a directly comparable siRNA and Eli Lilly is pursuing an oral small molecule. Being late into an outcomes trial in this category is a real disadvantage, and it is part of why Silence is seeking a partner with the scale to run one rather than starting alone.
Polycythemia vera and hematology
Divesiran would enter a market where Incyte's ruxolitinib and PharmaEssentia's ropeginterferon are established second-line options and Protagonist Therapeutics' rusfertide, partnered with Takeda, targets the same hepcidin biology through a peptide rather than gene silencing. Silence's differentiation rests on siRNA dosing intervals and durability of hematocrit control, which is exactly what the SANRECO Phase 2 data is meant to demonstrate.
What stocks are similar to Silence Therapeutics (SLN)?
Other names that sit close to SLN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Silence Therapeutics (SLN)
There are three common ways to get SLN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SLN sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where SLN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Silence Therapeutics (SLN)
SLN is a partner-dependent, data-dependent siRNA story. Divesiran's positive Phase 2 readout and a roughly $201 million raise in August 2026 shifted the question from whether the drug works to whether a Phase 3 starting in the first half of 2027 confirms it, and whether a large partner picks up zerlasiran.
More on Silence Therapeutics (SLN)
Whether SLN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SLN a buy or a sell?, and where the stock could go from here in the SLN stock forecast.
For income investors, whether SLN pays a dividend and how the payout looks is covered in does SLN pay a dividend? And to weigh SLN against a peer, read the full side-by-side comparisons: SLN vs ALNY and SLN vs ARWR.
Wondering how SLN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Silence Therapeutics
Ask Walnut's AI anything about SLN and see how it fits what you own.
FAQ
What does Silence Therapeutics actually do?
+
It designs short interfering RNA drugs that shut off production of a specific protein in liver cells before that protein is ever made. Its mRNAi GOLD platform attaches a GalNAc sugar to the siRNA so the liver absorbs it after a simple injection. The two lead candidates are zerlasiran for high lipoprotein(a) and divesiran for polycythemia vera.
Is SLN an ADS, and what is the ratio?
+
Yes. Silence Therapeutics plc is a UK company, and what trades on Nasdaq under SLN is an American Depositary Share representing 3 ordinary shares. Roughly 141.7 million ordinary shares were outstanding as of April 30, 2026, which corresponds to about 47 million ADSs. Any per-share figure sourced from the UK filings needs to be multiplied by three before it can be compared with the Nasdaq quote. The August 2026 offering added about 14.9 million ADSs, so the ADS-equivalent count is now meaningfully higher than the April figure.
Does Silence Therapeutics have any revenue?
+
Almost none. Trailing twelve-month revenue is roughly $0.6 million, all of it collaboration revenue recognized from the AstraZeneca agreement, down from about $34 million in fiscal 2024 when partnership milestones were flowing. The second quarter of 2026 recorded no revenue at all. The company has no approved product and no product sales, so the drop reflects the timing of partnership accounting rather than a business that shrank.
How much cash does it have, and how long does that last?
+
Cash and short-term investments were roughly $72 million as of June 30, 2026, guided at that point to fund operations into 2028 on the reduced spending plan. In August 2026 the company then closed an upsized offering of about 14.9 million ADSs at $13.50, for gross proceeds of about $201 million before fees. The third-quarter report, expected around November 5, 2026, should give the post-raise balance and any update to runway guidance; a divesiran Phase 3 will draw heavily on it.
Why did the stock roughly double over the past year?
+
Over the year to mid-2026 the shares rose on a sharp reduction in cash burn and on anticipation of the Phase 2 SANRECO topline for divesiran. The readout in August 2026 was positive, with an 88% responder rate versus 19% on placebo, and the stock reached a 52-week high of about $17.58. It has since pulled back hard, closing near $8.81 on October 16, 2026, below the $13.50 offering price. Measured from a year earlier the stock is up about 34%, and about 43% year to date, so the gain is far smaller than at the peak.
What happened with the AstraZeneca partnership?
+
AstraZeneca notified Silence on March 4, 2026 that it would not pursue development of SLN312 beyond Phase 1, and full global rights returned to Silence. The broader collaboration structure remains, but recognized revenue from it has fallen to a trickle. Regaining SLN312 gives Silence an additional asset to evaluate, though funding it independently would compete with the lead programs for the same limited cash.
Why has zerlasiran's Phase 3 not started?
+
By choice. Silence has said the program is Phase 3 ready and that core readiness activities are complete, but it will initiate the cardiovascular outcomes trial only after securing a third-party partner. Such trials enroll thousands of patients over several years and cost far more than the company's cash balance, so proceeding alone would mean either a very large raise or abandoning the discipline that produced the current runway.
How would someone hold SLN inside a thematic strategy?
+
SLN behaves like a single-catalyst clinical-stage biotech, meaning its price is driven by trial readouts and partnership news rather than by earnings or the broader market. Investors who hold names like this in a genetic-medicine or RNAi theme typically size the position small and pair it with commercial-stage peers, so one negative readout does not define the whole group. In Walnut, a stock like this would sit alongside its peers at a stated target weight, and the platform tracks how far the actual position has moved away from that target as prices swing.
What did the SANRECO Phase 2 trial of divesiran show?
+
Reported August 10, 2026: the trial met its primary endpoint, with 88% of divesiran patients responding (no phlebotomy and hematocrit below 45% in weeks 18-36) versus 19% on placebo. Response was 93.8% with every-6-week dosing and 81.3% with every-12-week dosing. Patients on divesiran averaged 0.2 phlebotomies over 36 weeks against 2.1 on placebo, and the drug was well tolerated with no new safety findings. A Phase 3 of every-12-week dosing is expected to start in the first half of 2027.
How has SLN stock performed in 2026?
+
SLN closed around $8.81 on October 16, 2026, up about 43% year to date and about 34% over one year, but down about 28% over the past month and well below its 52-week high of about $17.58. The shares spiked after the positive SANRECO data in August, the company sold new ADSs at $13.50, and the price has since slipped below that level. Six covering analysts carry a mean target of about $33. This is not investment advice.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Silence Therapeutics's investor relations page or your broker before making investment decisions.